Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 16, 2026

Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells
07:37

Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells

Published on: November 17, 2017

[Does plasmatic dilution influence the validity of PSA-tests?].

D Rohde1, V Mihelcic

  • 1Urologische Klinik, Klinikum Darmstadt. detlef.rohde@klinikum-darmstadt.de

Aktuelle Urologie
|March 29, 2007
PubMed
Summary

This study explores whether adjusting PSA test results for individual plasmatic volume improves cancer detection accuracy. Researchers analyzed patients who had prostate surgery and compared traditional PSA metrics with newly developed volume-adjusted parameters. They found that volume-based adjustments like PSAD and mPSAD (Vp) outperformed standard t-PSA in distinguishing benign from malignant conditions. The study suggests that incorporating physiological factors like blood volume could enhance diagnostic precision. While the results are promising, further research is needed to validate these metrics in larger populations. The authors propose that future diagnostic tools should integrate volume-based adjustments to improve prostate cancer detection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Exercise testing in respiratory medicine].

Pneumologie (Stuttgart, Germany)·2013
Same author

Interferon-alpha and gemcitabine (2',2'-difluorodeoxycytidine) in adult and pediatric renal tumors.

International journal of oncology·2011
Same author

Progress in the management of advanced renal cell carcinoma (RCC).

Aktuelle Urologie·2010
Same author

[Elevated PSA--what to do?].

MMW Fortschritte der Medizin·2008
Same author

[Off-label use: update and relevance for urology].

Aktuelle Urologie·2007
Same author

[Natural and artificial erections in spite of radical, non-nerve-sparing retropubic prostatectomy].

Aktuelle Urologie·2007

Area of Science:

  • Urological diagnostics within clinical oncology
  • Prostate cancer screening in medical testing

Background:

Prostate-specific antigen (PSA) testing remains a key diagnostic tool for prostate cancer. However, variability in PSA levels due to factors like blood volume can reduce test accuracy. Prior research has shown that PSA concentration alone may not reliably distinguish benign from malignant conditions. This gap motivated the exploration of volume-adjusted PSA metrics. No prior work had resolved how individual plasmatic volume affects diagnostic outcomes. Existing methods lack adjustments for physiological dilution effects. This paper's contribution is the introduction of modified PSA parameters. These new metrics aim to improve diagnostic precision by accounting for individual differences in blood volume. The study builds on established knowledge of PSA behavior in body fluids.

Purpose Of The Study:

This study aimed to assess whether adjusting PSA measurements for individual plasmatic volume improves diagnostic accuracy. Researchers focused on patients who underwent prostate surgery, including adenomectomy and radical prostatectomy. They sought to compare traditional PSA metrics with newly developed volume-adjusted parameters. The motivation was to address limitations in current diagnostic approaches. The specific problem was the potential inaccuracy caused by physiological dilution. The study's goal was to determine if volume-based adjustments enhance cancer detection. By analyzing PSA in relation to blood volume, the team aimed to refine diagnostic thresholds. The study sought to provide evidence for improved preoperative evaluation methods.

Keywords:
prostate cancer diagnosticsPSA test accuracyblood volume adjustmentPSA density metrics

Frequently Asked Questions

Volume-adjusted metrics like mPSAD (Vp) achieved higher AUCs (0.947) compared to traditional t-PSA (0.531), suggesting better diagnostic accuracy.

The formula was used to calculate mPSA (Vp) and mPSAD (Vp), which adjust PSA values based on individual plasmatic volume.

In this range, PSAD reached an AUC of 0.931, and mPSAD (Vp) achieved the highest AUC of 0.947, indicating improved cancer detection.

ROC curves were used to compare the sensitivity and specificity of t-PSA, PSAD, and mPSAD (Vp) across different PSA ranges.

More Related Videos

Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

Related Experiment Videos

Last Updated: Jul 16, 2026

Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells
07:37

Basic Research in Plasma Medicine - A Throughput Approach from Liquids to Cells

Published on: November 17, 2017

Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

Main Methods:

The research involved a retrospective analysis of patients who had undergone prostate surgery. Data were collected from 32 adenomectomy and 60 prostatectomy cases. Researchers calculated PSA density (PSAD) and two new metrics: mPSA (Vp) and mPSAD (Vp). These metrics adjusted PSA values based on individual plasmatic volume. The modified Retzlaff formula was used to derive these parameters. Receiver operating characteristic (ROC) curves were generated to compare diagnostic performance. Statistical analyses included area under the curve (AUC), sensitivity, and specificity. The study evaluated diagnostic accuracy across different PSA ranges and patient groups.

Main Results:

The study found that PSAD and mPSAD (Vp) significantly improved diagnostic accuracy compared to traditional t-PSA and mPSA (Vp). Within the full PSA range (0.1–88.4 microg/L), PSAD and mPSAD (Vp) achieved AUCs of 0.803 and 0.806, respectively. Traditional t-PSA and mPSA (Vp) had lower AUCs of 0.531. In the 4.0–10.0 microg/L range, PSAD reached an AUC of 0.931. mPSAD (Vp) achieved the highest AUC of 0.947 in this range. These results suggest volume-adjusted metrics enhance cancer detection. However, the improvement in mPSAD (Vp) did not reach statistical significance. The findings support the hypothesis that volume normalization improves PSA test validity.

Conclusions:

The authors propose that adjusting PSA measurements for individual plasmatic volume improves diagnostic accuracy. Their findings suggest that volume-adjusted metrics like PSAD and mPSAD (Vp) outperform traditional t-PSA in distinguishing benign from malignant conditions. The study highlights the potential of volume-based adjustments to refine cancer detection. These results may guide the development of more accurate preoperative diagnostic tools. The authors suggest that further research is needed to validate these metrics in larger populations. They emphasize the need for devices that measure prostate tissue volumes accurately. The study supports the idea that physiological factors should be integrated into PSA testing. The authors conclude that volume normalization could optimize the detection of curable prostate cancer cases.

PSAD and mPSAD (Vp) showed significantly higher AUCs (0.803 and 0.806) compared to t-PSA (0.531) in the full PSA range.

The authors propose that volume-adjusted PSA metrics could optimize detection by integrating physiological factors into testing.